Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Development and Reliability of the Joint Tissue Activity and Damage Examination for Quantitation of Structural Abnormalities by Musculoskeletal Ultrasound in Hemophilic Joints.

Volland LM, Zhou JY, Barnes RFW, Kruse-Jarres R, Steiner B, Quon DV, Bailey C, Hughes TH, Moore RE, Chang EY, von Drygalski A.

J Ultrasound Med. 2019 Jun;38(6):1569-1581. doi: 10.1002/jum.14846. Epub 2018 Oct 29.

PMID:
30371941
2.

A cross-sectional analysis of cardiovascular disease in the hemophilia population.

Sood SL, Cheng D, Ragni M, Kessler CM, Quon D, Shapiro AD, Key NS, Manco-Johnson MJ, Cuker A, Kempton C, Wang TF, Eyster ME, Kuriakose P, von Drygalski A, Gill JC, Wheeler A, Kouides P, Escobar MA, Leissinger C, Galdzicka S, Corson M, Watson C, Konkle BA.

Blood Adv. 2018 Jun 12;2(11):1325-1333. doi: 10.1182/bloodadvances.2018018226.

3.

Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (P-FiQ) study.

Buckner TW, Batt K, Quon D, Witkop M, Recht M, Kessler C, Baumann K, Hernandez G, Wang M, Cooper DL, Kempton CL.

Eur J Haematol. 2018 Apr;100 Suppl 1:5-13. doi: 10.1111/ejh.13027.

PMID:
29498784
4.

Patient-reported outcomes and joint status across subgroups of US adults with hemophilia with varying characteristics: Results from the Pain, Functional Impairment, and Quality of Life (P-FiQ) study.

Batt K, Boggio L, Neff A, Buckner TW, Wang M, Quon D, Witkop M, Recht M, Kessler C, Iyer NN, Cooper DL.

Eur J Haematol. 2018 Apr;100 Suppl 1:14-24. doi: 10.1111/ejh.13028.

PMID:
29498783
5.

Pocket handheld ultrasound for evaluation of the bleeding haemophilic joint: A novel and reliable way to recognize joint effusions.

Zhou JY, Rappazzo KC, Volland L, Barnes RFW, Brackman M, Steiner B, Kruse-Jarres R, Quon DV, Bailey C, Chang EY, von Drygalski A.

Haemophilia. 2018 Mar;24(2):e77-e80. doi: 10.1111/hae.13429. Epub 2018 Feb 12. No abstract available.

PMID:
29436079
6.

Common Data Elements for Concussion in Tertiary Care: Phase One in Ontario.

Hunt C, Michalak A, Ouchterlony D, Marshall S, Masanic C, Vaidyanath C, Bhalerao S, Cusimano MD, Quon D, Fischer LK, Baker A.

Can J Neurol Sci. 2017 Nov;44(6):676-683. doi: 10.1017/cjn.2017.222.

PMID:
29391082
7.

Impact of pain and functional impairment in US adults with haemophilia: Patient-reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P-FiQ) study.

Kempton CL, Recht M, Neff A, Wang M, Buckner TW, Soni A, Quon D, Witkop M, Boggio L, Gut RZ, Cooper DL.

Haemophilia. 2018 Mar;24(2):261-270. doi: 10.1111/hae.13377. Epub 2017 Dec 8.

PMID:
29218759
8.

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.

Collins PW, Quon DVK, Makris M, Chowdary P, Kempton CL, Apte SJ, Ramanan MV, Hay CRM, Drobic B, Hua Y, Babinchak TJ, Gomperts ED.

Haemophilia. 2018 Jan;24(1):104-112. doi: 10.1111/hae.13324. Epub 2017 Aug 17.

9.

PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.

Wang M, Lawrence JB, Quon DV, Ducore J, Simpson ML, Boggio LN, Mitchell IS, Yuan G, Alexander WA, Schved JF.

Haemophilia. 2017 Nov;23(6):832-843. doi: 10.1111/hae.13301. Epub 2017 Aug 3.

PMID:
28776894
10.

Perioperative management of haemophilia B: A critical appraisal of the evidence and current practices.

Neufeld EJ, Solimeno L, Quon D, Walsh C, Seremetis S, Cooper D, Iyer NN, Hoxer CS, Giangrande P.

Haemophilia. 2017 Nov;23(6):821-831. doi: 10.1111/hae.13279. Epub 2017 Jul 27. Review.

PMID:
28752639
11.

Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study.

Witkop M, Neff A, Buckner TW, Wang M, Batt K, Kessler CM, Quon D, Boggio L, Recht M, Baumann K, Gut RZ, Cooper DL, Kempton CL.

Haemophilia. 2017 Jul;23(4):556-565. doi: 10.1111/hae.13214. Epub 2017 Apr 16.

PMID:
28419637
12.

Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A.

Shapiro AD, Mahlangu JN, Perry D, Pasi J, Quon DV, Chowdary P, Tsao E, Li S, Innes A, Pierce GF, Allen GA.

Haemophilia. 2017 May;23(3):392-399. doi: 10.1111/hae.13144. Epub 2017 Feb 20.

PMID:
28220631
13.

The Hypertension of Hemophilia Is Not Explained by the Usual Cardiovascular Risk Factors: Results of a Cohort Study.

Barnes RF, Cramer TJ, Sait AS, Kruse-Jarres R, Quon DV, von Drygalski A.

Int J Hypertens. 2016;2016:2014201. Epub 2016 Nov 14.

14.

Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies.

Quon DV, Klamroth R, Kulkarni R, Shapiro AD, Baker RI, Castaman G, Kerlin BA, Tsao E, Allen G.

Haemophilia. 2017 Jan;23(1):e39-e42. doi: 10.1111/hae.13125. Epub 2016 Dec 11. No abstract available.

PMID:
27943467
16.

In My Athletic Trainer's Bag.

Quon D.

Am J Orthop (Belle Mead NJ). 2016 Sep/Oct;45(6):376. No abstract available.

PMID:
27737283
17.

Women leaders in hematology: Inspirations & insights.

Quon D, Chitlur M, Rajpurkar M, Simpson M, O'Brien S, Flood V, Hsieh L, Acharya S, Kruse-Jarres R, Sood S, Maahs J.

Am J Hematol. 2016 Apr;91 Suppl 1:S6-S34. doi: 10.1002/ajh.24316. No abstract available.

18.

Unmet needs in the transition to adulthood: 18- to 30-year-old people with hemophilia.

Quon D, Reding M, Guelcher C, Peltier S, Witkop M, Cutter S, Buranahirun C, Molter D, Frey MJ, Forsyth A, Tran DB, Curtis R, Hiura G, Levesque J, de la Riva D, Compton M, Iyer NN, Holot N, Cooper DL.

Am J Hematol. 2015 Dec;90 Suppl 2:S17-22. doi: 10.1002/ajh.24219. Review.

19.

Challenges in transition to adulthood for young adult patients with hemophilia: Quantifying the psychosocial issues and developing solutions.

Witkop M, Guelcher C, Forsyth A, Quon D, Hawk S, Curtis R, Cutter S, Molter D, Cooper DL.

Am J Hematol. 2015 Dec;90 Suppl 2:S1-2. doi: 10.1002/ajh.24217. No abstract available.

20.

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.

Chawla SP, Chua VS, Hendifar AF, Quon DV, Soman N, Sankhala KK, Wieland DS, Levitt DJ.

Cancer. 2015 Feb 15;121(4):570-9. doi: 10.1002/cncr.29081. Epub 2014 Oct 13.

21.

Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.

Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, Pasi KJ, Hanabusa H, Pabinger I, Mahlangu J, Fogarty P, Lillicrap D, Kulke S, Potts J, Neelakantan S, Nestorov I, Li S, Dumont JA, Jiang H, Brennan A, Pierce GF.

J Thromb Haemost. 2014 Nov;12(11):1788-800. doi: 10.1111/jth.12723. Epub 2014 Oct 10.

22.

Prevalence and risk factors for hypertension in hemophilia.

von Drygalski A, Kolaitis NA, Bettencourt R, Bergstrom J, Kruse-Jarres R, Quon DV, Wassel C, Li MC, Waalen J, Elias DJ, Mosnier LO, Allison M.

Hypertension. 2013 Jul;62(1):209-15. doi: 10.1161/HYPERTENSIONAHA.113.01174. Epub 2013 Apr 29.

23.

Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.

Martinowitz U, Shapiro A, Quon DV, Escobar M, Kempton C, Collins PW, Chowdary P, Makris M, Mannucci PM, Morfini M, Valentino LA, Gomperts E, Lee M.

Haemophilia. 2012 Nov;18(6):881-7. doi: 10.1111/j.1365-2516.2012.02897.x. Epub 2012 Jul 5.

PMID:
22764744
24.

Management of bleeding disorders in the elderly.

Kruse-Jarres R, Quon D, Schramm W, Dolan G.

Haemophilia. 2012 May;18 Suppl 2:37-45. doi: 10.1111/j.1365-2516.2012.02798.x.

PMID:
22530577
25.

A qualitative study of factors influencing the decision to have an elective amputation.

Quon DL, Dudek NL, Marks M, Boutet M, Varpio L.

J Bone Joint Surg Am. 2011 Nov 16;93(22):2087-92. doi: 10.2106/JBJS.J.01998.

PMID:
22262380
26.

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E, Jiang H, Li L, Dumont JA, Goyal J, Zhang X, Sommer J, McCue J, Barbetti M, Luk A, Pierce GF.

Blood. 2012 Mar 29;119(13):3031-7. doi: 10.1182/blood-2011-09-382846. Epub 2012 Jan 5.

27.

A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management.

Valentino LA, Mamonov V, Hellmann A, Quon DV, Chybicka A, Schroth P, Patrone L, Wong WY; Prophylaxis Study Group.

J Thromb Haemost. 2012 Mar;10(3):359-67. doi: 10.1111/j.1538-7836.2011.04611.x.

28.

The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience.

Kurth M, Puetz J, Kouides P, Sanders J, Sexauer C, Bernstein J, Gruppo R, Manco-Johnson M, Neufeld EJ, Rodriguez N, Wicklund B, Quon D, Aledort L.

J Thromb Haemost. 2011 Nov;9(11):2229-34. doi: 10.1111/j.1538-7836.2011.04493.x.

29.

Role of exercise and physical activity on haemophilic arthropathy, fall prevention and osteoporosis.

Forsyth AL, Quon DV, Konkle BA.

Haemophilia. 2011 Sep;17(5):e870-6. doi: 10.1111/j.1365-2516.2011.02514.x. Epub 2011 Mar 24. Review.

PMID:
21435116
31.

How we treat: haematuria in adults with haemophilia.

Quon DV, Konkle BA.

Haemophilia. 2010 Jul 1;16(4):683-5. doi: 10.1111/j.1365-2516.2009.02171.x. Epub 2009 Dec 23. No abstract available.

PMID:
20041958
32.

Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.

Chawla SP, Chua VS, Fernandez L, Quon D, Blackwelder WC, Gordon EM, Hall FL.

Mol Ther. 2010 Feb;18(2):435-41. doi: 10.1038/mt.2009.228. Epub 2009 Oct 13.

33.

Emerging clinical concerns in the ageing haemophilia patient.

Konkle BA, Kessler C, Aledort L, Andersen J, Fogarty P, Kouides P, Quon D, Ragni M, Zakarija A, Ewenstein B.

Haemophilia. 2009 Nov;15(6):1197-209. doi: 10.1111/j.1365-2516.2009.02066.x. Epub 2009 Jul 21. Review.

PMID:
19686466
34.

Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma.

Chawla SP, Chua VS, Fernandez L, Quon D, Saralou A, Blackwelder WC, Hall FL, Gordon EM.

Mol Ther. 2009 Sep;17(9):1651-7. doi: 10.1038/mt.2009.126. Epub 2009 Jun 16.

35.

A dynamin is required for the biogenesis of secretory organelles in Toxoplasma gondii.

Breinich MS, Ferguson DJ, Foth BJ, van Dooren GG, Lebrun M, Quon DV, Striepen B, Bradley PJ, Frischknecht F, Carruthers VB, Meissner M.

Curr Biol. 2009 Feb 24;19(4):277-86. doi: 10.1016/j.cub.2009.01.039. Epub 2009 Feb 12.

36.

Directly dated starch residues document early formative maize (Zea mays L.) in tropical Ecuador.

Zarrillo S, Pearsall DM, Raymond JS, Tisdale MA, Quon DJ.

Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5006-11. doi: 10.1073/pnas.0800894105. Epub 2008 Mar 24.

37.

Inter- and intra-observer reliability of radiographic scores commonly used for the evaluation of haemophilic arthropathy.

Silva M, Luck JV Jr, Quon D, Young CR, Chin DM, Ebramzadeh E, Fong YJ.

Haemophilia. 2008 May;14(3):504-12. doi: 10.1111/j.1365-2516.2007.01630.x. Epub 2008 Jan 22.

PMID:
18218011
38.

Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.

Gaspar NJ, Li L, Kapoun AM, Medicherla S, Reddy M, Li G, O'Young G, Quon D, Henson M, Damm DL, Muiru GT, Murphy A, Higgins LS, Chakravarty S, Wong DH.

Mol Pharmacol. 2007 Jul;72(1):152-61. Epub 2007 Mar 30.

PMID:
17400764
39.

Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression.

Kapoun AM, Gaspar NJ, Wang Y, Damm D, Liu YW, O'young G, Quon D, Lam A, Munson K, Tran TT, Ma JY, Murphy A, Dugar S, Chakravarty S, Protter AA, Wen FQ, Liu X, Rennard SI, Higgins LS.

Mol Pharmacol. 2006 Aug;70(2):518-31. Epub 2006 May 17.

PMID:
16707625
40.

Peer validation of a method to confirm chloramphenicol in honey by liquid chromatography-tandem mass spectrometry.

Quon D, Carson MC, Nochetto C, Heller DN, Butterworth F.

J AOAC Int. 2006 Mar-Apr;89(2):586-93.

PMID:
16640310
41.

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.

Nguyen AN, Stebbins EG, Henson M, O'Young G, Choi SJ, Quon D, Damm D, Reddy M, Ma JY, Haghnazari E, Kapoun AM, Medicherla S, Protter A, Schreiner GF, Kurihara N, Anderson J, Roodman GD, Navas TA, Higgins LS.

Exp Cell Res. 2006 Jun 10;312(10):1909-23. Epub 2006 Apr 4.

PMID:
16600214
42.

Same day outpatient transjugular liver biopsies in haemophilia.

Saab S, Cho D, Quon DV, Ibrahim AB, Dong P, Marder V, Logan L.

Haemophilia. 2004 Nov;10(6):727-31.

PMID:
15569168
43.

B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation.

Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA.

Circ Res. 2004 Mar 5;94(4):453-61. Epub 2004 Jan 15.

PMID:
14726474
44.

Positive and negative regulation of APP amyloidogenesis by sumoylation.

Li Y, Wang H, Wang S, Quon D, Liu YW, Cordell B.

Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):259-64. Epub 2002 Dec 27. Erratum in: Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):9102.

45.
46.

Processing of beta-amyloid precursor protein by cathepsin D.

Higaki J, Catalano R, Guzzetta AW, Quon D, Navé JF, Tarnus C, D'Orchymont H, Cordell B.

J Biol Chem. 1996 Dec 13;271(50):31885-93.

48.

Early Alzheimer disease-like histopathology increases in frequency with age in mice transgenic for beta-APP751.

Higgins LS, Rodems JM, Catalano R, Quon D, Cordell B.

Proc Natl Acad Sci U S A. 1995 May 9;92(10):4402-6.

49.
50.

beta-Amyloid peptide produced in vitro is degraded by proteinases released by cultured cells.

Naidu A, Quon D, Cordell B.

J Biol Chem. 1995 Jan 20;270(3):1369-74.

Supplemental Content

Support Center